Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.30
AVDL's Cash-to-Debt is ranked lower than
77% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. AVDL: 1.30 )
Ranked among companies with meaningful Cash-to-Debt only.
AVDL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 9.91 Max: 352.34
Current: 1.3
0.08
352.34
Equity-to-Asset 0.27
AVDL's Equity-to-Asset is ranked lower than
86% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AVDL: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
AVDL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.48 Max: 0.8
Current: 0.27
-0.32
0.8
Debt-to-Equity 1.44
AVDL's Debt-to-Equity is ranked lower than
89% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. AVDL: 1.44 )
Ranked among companies with meaningful Debt-to-Equity only.
AVDL' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.99  Med: 0.06 Max: 10.98
Current: 1.44
-8.99
10.98
Debt-to-EBITDA 2.86
AVDL's Debt-to-EBITDA is ranked lower than
64% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. AVDL: 2.86 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AVDL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.98  Med: -0.72 Max: 2.86
Current: 2.86
-5.98
2.86
Piotroski F-Score: 2
Altman Z-Score: 0.19
Beneish M-Score: -2.22
WACC vs ROIC
20.80%
-61.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.03
AVDL's Operating Margin % is ranked higher than
66% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. AVDL: -11.03 )
Ranked among companies with meaningful Operating Margin % only.
AVDL' s Operating Margin % Range Over the Past 10 Years
Min: -611.75  Med: -28.65 Max: 58.79
Current: -11.03
-611.75
58.79
Net Margin % -1.64
AVDL's Net Margin % is ranked higher than
71% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. AVDL: -1.64 )
Ranked among companies with meaningful Net Margin % only.
AVDL' s Net Margin % Range Over the Past 10 Years
Min: -1027.16  Med: -27.32 Max: 39.41
Current: -1.64
-1027.16
39.41
ROE % -2.64
AVDL's ROE % is ranked higher than
76% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. AVDL: -2.64 )
Ranked among companies with meaningful ROE % only.
AVDL' s ROE % Range Over the Past 10 Years
Min: -1111.21  Med: -23.96 Max: 106.97
Current: -2.64
-1111.21
106.97
ROA % -0.78
AVDL's ROA % is ranked higher than
78% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AVDL: -0.78 )
Ranked among companies with meaningful ROA % only.
AVDL' s ROA % Range Over the Past 10 Years
Min: -58.85  Med: -12.24 Max: 27.38
Current: -0.78
-58.85
27.38
ROC (Joel Greenblatt) % 1104.98
AVDL's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. AVDL: 1104.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVDL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4050.11  Med: -42.51 Max: 3538.48
Current: 1104.98
-4050.11
3538.48
3-Year Revenue Growth Rate 115.60
AVDL's 3-Year Revenue Growth Rate is ranked higher than
95% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AVDL: 115.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVDL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: 0.8 Max: 181.1
Current: 115.6
-52.4
181.1
GuruFocus has detected 3 Warning Signs with Avadel Pharmaceuticals PLC AVDL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVDL's 30-Y Financials

Financials (Next Earnings Date: 2018-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AVDL Guru Trades in Q3 2017

Jim Simons 823,700 sh (+17.96%)
» More
Q4 2017

AVDL Guru Trades in Q4 2017

Charles Brandes 3,308,250 sh (New)
Jim Simons 1,144,600 sh (+38.96%)
» More
Q1 2018

AVDL Guru Trades in Q1 2018

Charles Brandes 4,808,493 sh (+45.35%)
Jim Simons 781,800 sh (-31.70%)
» More
Q2 2018

AVDL Guru Trades in Q2 2018

Jim Simons 1,049,070 sh (+34.19%)
Charles Brandes 4,970,106 sh (+3.36%)
» More
» Details

Insider Trades

Latest Guru Trades with AVDL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2018-08-31 Add 24.30%0.14%Premium Member Access $5.13 $ 4.50-12%6,177,794
Charles Brandes 2018-06-30 Add 3.36%0.02%$5.89 - $7.78 $ 4.50-36%4,970,106
Charles Brandes 2018-03-31 Add 45.35%0.23%$6.76 - $11.7 $ 4.50-49%4,808,493
Charles Brandes 2018-03-29 Add 45.35%0.22%Premium Member Access $7.29 $ 4.50-38%4,808,493
Charles Brandes 2017-12-31 New Buy0.55%$8.03 - $11.25 $ 4.50-52%3,308,250
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OSL:BGBIO, XKRX:007630, MIL:MLM, BOM:531349, XKRX:046210, NAS:SELB, LSE:OBD, NAS:KIN, NAS:TYME, NAS:MBIO, OTCPK:OSIR, XKRX:064550, AMEX:XXII, ROCO:6575, WAR:SLV, NAS:TORC, ASX:PNV, NAS:NERV, NAS:ASNS, TSE:4571 » details
Traded in other countries:AWK1.Germany,
Headquarter Location:Ireland
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company developing and commercializing pharmaceutical products. The company's products include Bloxiverz, Vazculep, Akovaz, Karbinal ER, AcipHex Sprinkle, Cefaclor and Flexichamber.

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Top Ranked Articles about Avadel Pharmaceuticals PLC

The medical condition 72 percent of Americans don’t know about is stealing sleep and disrupting lives, survey shows
Brandes Investments Expands Stake in Avadel Pharmaceuticals Firm that seeks mispricings buys as share fall
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (NASDAQ:AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Read more...
Avadel Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference
New Data on NOCTIVA™ Presented at the 2018 International Continence Society Meeting
Avadel Pharmaceuticals to Report Second Quarter 2018 Results
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp — Research Highlights Growth, Revenue, and Consolidated Results
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting
Avadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

Ratios

vs
industry
vs
history
PB Ratio 2.07
AVDL's PB Ratio is ranked higher than
71% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AVDL: 2.07 )
Ranked among companies with meaningful PB Ratio only.
AVDL' s PB Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.64 Max: 71.87
Current: 2.07
1.84
71.87
PS Ratio 1.28
AVDL's PS Ratio is ranked higher than
92% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AVDL: 1.28 )
Ranked among companies with meaningful PS Ratio only.
AVDL' s PS Ratio Range Over the Past 10 Years
Min: 1.22  Med: 4.46 Max: 799.47
Current: 1.28
1.22
799.47
EV-to-EBIT 4.03
AVDL's EV-to-EBIT is ranked higher than
83% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AVDL: 4.03 )
Ranked among companies with meaningful EV-to-EBIT only.
AVDL' s EV-to-EBIT Range Over the Past 10 Years
Min: -88.3  Med: -6.6 Max: 89.5
Current: 4.03
-88.3
89.5
EV-to-EBITDA 3.32
AVDL's EV-to-EBITDA is ranked higher than
84% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AVDL: 3.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVDL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -304  Med: -6.2 Max: 76.3
Current: 3.32
-304
76.3
EV-to-Revenue 0.95
AVDL's EV-to-Revenue is ranked higher than
96% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AVDL: 0.95 )
Ranked among companies with meaningful EV-to-Revenue only.
AVDL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 3.9 Max: 248
Current: 0.95
0.9
248
Current Ratio 3.39
AVDL's Current Ratio is ranked lower than
60% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AVDL: 3.39 )
Ranked among companies with meaningful Current Ratio only.
AVDL' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.73 Max: 6.76
Current: 3.39
0.57
6.76
Quick Ratio 3.28
AVDL's Quick Ratio is ranked lower than
59% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AVDL: 3.28 )
Ranked among companies with meaningful Quick Ratio only.
AVDL' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.62 Max: 6.7
Current: 3.28
0.52
6.7
Days Inventory 119.81
AVDL's Days Inventory is ranked higher than
52% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. AVDL: 119.81 )
Ranked among companies with meaningful Days Inventory only.
AVDL' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 100.4 Max: 1457.72
Current: 119.81
51.05
1457.72
Days Sales Outstanding 39.82
AVDL's Days Sales Outstanding is ranked higher than
72% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AVDL: 39.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVDL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.8  Med: 69.78 Max: 541.87
Current: 39.82
15.8
541.87
Days Payable 227.21
AVDL's Days Payable is ranked higher than
82% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. AVDL: 227.21 )
Ranked among companies with meaningful Days Payable only.
AVDL' s Days Payable Range Over the Past 10 Years
Min: 161.48  Med: 228.67 Max: 3311.63
Current: 227.21
161.48
3311.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 21.20
AVDL's 3-Year Average Share Buyback Ratio is ranked higher than
100% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AVDL: 21.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVDL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7  Med: -7.8 Max: 21.2
Current: 21.2
-47.7
21.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.29
AVDL's Price-to-Median-PS-Value is ranked higher than
87% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AVDL: 0.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVDL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.27 Max: 187.5
Current: 0.29
0.27
187.5
Earnings Yield (Greenblatt) % 24.67
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AVDL: 24.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVDL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.5  Med: -7.3 Max: 49.3
Current: 24.67
-28.5
49.3

More Statistics

Revenue (TTM) (Mil) $136.95
EPS (TTM) $ -0.07
Beta3.06
Volatility50.27%
52-Week Range $4.18 - 11.93
Shares Outstanding (Mil)36.76 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 118 134 217
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 1.65 -1.10 0.16
EPS without NRI ($) 1.65 -1.10 0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}